Aspira Womens Health (AWH, Financial) experienced a significant stock price drop of 7.80%, reaching $0.775 per share. The trading volume stood at 14,064 shares with a turnover rate of 0.09% and a volatility of 7.47%.
Recent financial results for Aspira Womens Health revealed an operating revenue of $2.42 million and a net loss of $3.53 million, resulting in an earnings per share (EPS) of -$0.28. The gross profit was recorded at $1.42 million, with a price-to-earnings ratio of -0.57. Currently, no institutional ratings, such as buy, hold, or sell recommendations, are available for the stock.
Within the life sciences sector, there was an overall decline of 0.20%. However, some stocks showed notable performance, with Volitionrx Limited, Neuronetics, Inc., and Personalis, Inc. registering significant gains. Meanwhile, Applied Dna Sciences, Inc., Ispecimen Inc., and Mainz Biomed N.V. showed high activity with turnover rates of 15.59%, 10.09%, and 6.70%, respectively. Stocks with high volatility included Burning Rock Biotech, Check-Cap Ltd., and Bioaffinity Technologies Inc C/Wts 07/09/2027 (To Pur Com), with volatilities of 62.64%, 19.15%, and 14.17%, respectively.
Aspira Womens Health specializes in developing and commercializing diagnostic tests for gynecological diseases. Their products include the OvaSuite, a series of blood tests using proprietary algorithms; OvaWatch, which evaluates ovarian cancer risk in women with adnexal mass; and Ova1Plus, a combination of two FDA-approved tests for women planning surgery for pelvic masses.
